April 2015: New DNA Damage (8-OH-dG) Kit Formulation- Launching in May!

DNA Damage 8-OHdG

January 2015: Happy New Year 2015 to our Dear Customers!


Happy New Year 2015 from MBIO
~ Team MBIO

December 2014: Merry Christmas and Happy New Year 2015!

As 2014 comes to a close and we look forward to 2015, we want to say thank you for your ongoing trust and business.

We look forward to enabling your ground-breaking research in 2015. Wishing you continued success in your research!



~ Team MBIO

Merry Christmas

October 2014: New Exclusive Distributorship with Bio-Gems

MBIO is proud to announce our new partnership with BioGems International (California, USA) and we are now the exclusive distributor for BioGems in Malaysia. MBIO offers a comprehensive portfolio of Flow Cytometry reagents to Malaysia research communities through BioGems. For time limited period, we are now offering BioGems at special introductory price. Contact us today!

ABOUT BIOGEMS INTERNATIONAL INC. (California, USA):

BioGems offers conjugated antibodies validated for flow cytometry, including CD and other markers of key cellular processes, antibodies optimized for use in functional and in vivo studies, isotype controls, buffers, dyes and more. Beyond the essentials of flow cytometry research, BioGems has the relevant reagents for Angiogenesis, Cancer, Apoptosis, Stem Cell, Innate Immunity, and Adaptive Immunity research. BioGems line of products is rapidly growing and we work with our customers to guide us in new product development.

BioGems offers conjugated antibodies validated for flow cytometry, including CD and other markers of key cellular processes, antibodies optimized for use in functional and in vivo studies, isotype controls, buffers, dyes and more.

View BioGems's Flow Essentials Products here»

Biogems-MBIO

May 2013: New markers for lung carcinomas (Zytomed Systems, Germany)

P40 and MAdL: excellent new markers for lung carcinomas. Due to new therapies available for the treatment of lung cancer it becomes more and more important to discriminate between the different subtypes of pulmonary cancers.

p40
Several studies showed that p63, the most commonly used antibody for detecting lung squamous cell carcinomas, shows a high sensitvity but is not entirely specific for squamous cell carcinoma as it detects also adenocarcinomas. in up to 30% of all cases (Au et al. 2004).

The p40 protein, an N-terminal truncated form of p63 protein (ΔNp63), seems to be more strictly bound to squamous cell carcinomas than p63.p40 staining is equivalent to p63 in sensitivity for squamous cell carcinoma but shows a considerably higher specificity ( Bishop et al, Pelosi et al. and Nonaka, 2012). 
A recent study also indicates that detection of basal cells in prostate by p40 is superior to detection by p63. (Sailer et al. 2013).

MAdL
MAdL (Marker for Adenocarcinomas of the Lung) is a new specific marker for lung adenocarcinomas. The antibody shows a higher sensitivity and specificity than commonly used markers like TTF1 and Napsin A. MAdL is not expressed in small-cell lung carcinomas and carcinoids and the expression of MAdL remains constant with increasing malignity of the tumour. (Schultz H et al. 2011). Extensive testing has shown that MAdL immunohistochemistry on formalin-fixed tissue works best after proteolytic digestion (i.e. Pepsin, ZUC038-060).

Read more about these new markers at Zytomed»


June 2014: New Glycine ELISA for Urine Samples (LDN, Germany)


Why measuring Glycine?

The detection of glycine is indicated in a wide variety of diseases ranging from infarction, tumor, leukoencephalopathies, infection to gliosis. In addition studies show that Glycine may help to improve memory retrieval in individuals with a wide variety of sleep-depriving conditions, including jet lag and overwork.

As a nutrient Glycine has been used to: (1) prevent tissue injury; (2) enhance anti-oxidative capacity; (3) promote protein synthesis and wound healing; (4) improve immunity; and (5) treat metabolic disorders in obesity, diabetes, cardiovascular disease, ischemia-reperfusion injuries, cancers, and various inflammatory diseases.

Glycine ELISA (BA E-2100)

It’s with pleasure to inform you that LDN has introduced an ELISA for the quantitative determination of Glycine in urine samples. Glycine is an amino acid which is considered as the most important inhibitory neurotransmitter in the central nervous system, especially in the spinal cord, brainstem, and retina and plays a key role in metabolic regulation, anti-oxidative reactions, and neurological function. Therefore detection of glycine is indicated in a wide variety of diseases ranging from infarction, tumor, leukoencephalopathies, infection to gliosis.

  • Product Name : Glycine ELISA
  • Catalog No. : BA E-2100
  • Description : Enzyme immunoassay (ELISA) for the quantitative determination of Glycine in urine
  • Sample Type/Volume: 20 µl urine
  • Design : Common sample preparation. Derivatization in liquid phase (96-well-reaction plate). Immunoassay using 12x8 break apart wells microtiter plate (precoated). 6 standards, 2 controls; ready for use.
  • Assay Time : Sample preparation and derivatization 2.5 hours; ELISA overnight, 2 x 30 min
  • Sensitivity : 3.3 µg/ml
  • Storage : 2 - 8 °C
  • Regulatory Status : RUO
  • Kit size : 96 determinations
You can download the LDN's Glycine ELISA kit test instruction here:

or

Link to LDN